Taysha Gene Therapies (TSHA) Return on Capital Employed (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Return on Capital Employed of 43.93% for Q1 2026, up 2590.0% on a YoY basis from 1.63% in Q1 2025, and down 20.62% sequentially from 36.42% in Q4 2025.
Taysha Gene Therapies (TSHA) Return on Capital Employed (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Return on Capital Employed data on file, last reported at 43.93% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2590.0% year-over-year to 43.93%; the trailing twelve-month figure through Mar 2026 stood at 43.93% (up 2590.0% YoY), and the FY2025 full-year result was 49.05%, up 1613.0% from the prior year.
- Return on Capital Employed slipped to 43.93% in Q1 2026, from 36.42% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 263.57% in Q3 2023 to a low of 291.63% in Q2 2023.
- A 5-year average of 89.39% and a median of 63.49% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 43230 bps in 2023 and sank 31810 bps in 2024, its largest moves.
- Tracing TSHA's Return on Capital Employed over 5 years: stood at 289.66% in 2022, then surged by 83 bps to 49.11% in 2023, then slipped by 29 bps to 63.49% in 2024, then soared by 43 bps to 36.42% in 2025, then dropped by 21 bps to 43.93% in 2026.
- Business Quant data shows TSHA's Return on Capital Employed at 43.93% in Q1 2026, 36.42% in Q4 2025, and 34.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Taysha Gene Therapies | 2.05 Bn | 2.05 Bn | - | -43.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.93% |
| Dec 31, 2025 | -36.42% |
| Sep 30, 2025 | -34.47% |
| Jun 30, 2025 | -44.66% |
| Mar 31, 2025 | -69.83% |
| Dec 31, 2024 | -63.49% |
| Sep 30, 2024 | -54.53% |
| Jun 30, 2024 | -54.82% |
| Mar 31, 2024 | -64.57% |
| Dec 31, 2023 | -49.11% |
| Sep 30, 2023 | 263.57% |
| Jun 30, 2023 | -291.63% |
| Mar 31, 2023 | -217.47% |
| Dec 31, 2022 | -289.66% |
| Sep 30, 2022 | -168.73% |
| Jun 30, 2022 | -164.95% |
| Mar 31, 2022 | -135.00% |
| Dec 31, 2021 | -98.59% |
| Sep 30, 2021 | -71.59% |
| Jun 30, 2021 | -49.67% |